Cydan Development is an orphan drug accelerator that identifies and de-risks programs with therapeutic and commercial potential. Cydan focuses on selecting promising assets with well-understood biology and proof-of-concept data in in vivo models from academia, industry and other sources. Data generated during a rigorous de-risking process enables formation of stand-alone companies and strategic partnerships.
01.06.16: Vtesse, Inc. Announces FDA’s Granting of Breakthrough Therapy Designation for VTS-270 in Niemann-Pick Type C1 Disease
11.04.15: Cydan Announces the Promotion of Dione Kobayashi,
Ph.D., to Vice President, Preclinical Translation
09.28.15: Vtesse, Inc. Initiates Phase 2b/3 Clinical Trial of VTS-270 for Treatment of Niemann-Pick Type C1 (NPC) Disease